WO2001039796A3 - Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides - Google Patents

Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides Download PDF

Info

Publication number
WO2001039796A3
WO2001039796A3 PCT/CA2000/001413 CA0001413W WO0139796A3 WO 2001039796 A3 WO2001039796 A3 WO 2001039796A3 CA 0001413 W CA0001413 W CA 0001413W WO 0139796 A3 WO0139796 A3 WO 0139796A3
Authority
WO
WIPO (PCT)
Prior art keywords
alzheimer
prevention
treatment
vaccine
related diseases
Prior art date
Application number
PCT/CA2000/001413
Other languages
English (en)
Other versions
WO2001039796A2 (fr
Inventor
Robert Chalifour
Lise Hebert
Xianqi Kong
Francine Gervais
Original Assignee
Neurochem Inc
Robert Chalifour
Lise Hebert
Xianqi Kong
Francine Gervais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0016022-9A priority Critical patent/BR0016022A/pt
Priority to KR1020027006845A priority patent/KR20020073341A/ko
Priority to IL14992400A priority patent/IL149924A0/xx
Priority to EP00981111A priority patent/EP1235587A2/fr
Priority to MXPA02005576A priority patent/MXPA02005576A/es
Priority to CA002388559A priority patent/CA2388559A1/fr
Application filed by Neurochem Inc, Robert Chalifour, Lise Hebert, Xianqi Kong, Francine Gervais filed Critical Neurochem Inc
Priority to AU18473/01A priority patent/AU784312B2/en
Priority to JP2001541528A priority patent/JP2004500354A/ja
Publication of WO2001039796A2 publication Critical patent/WO2001039796A2/fr
Publication of WO2001039796A3 publication Critical patent/WO2001039796A3/fr
Priority to NO20022531A priority patent/NO20022531L/no
Priority to HK03100407.4A priority patent/HK1049279A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un vaccin à antigène « non-soi » à base stéréochimique, destiné à la prévention et/ou au traitement de la maladie d'Alzheimer et d'autres maladies associées aux substances amyloïdes. Le vaccin destiné à la prévention et/ou au traitement de la maladie d'Alzheimer et d'autres maladies associées aux substances amyloïdes selon cette invention surmonte les inconvénients associés à l'utilisation de peptides, de protéines et d'immunogènes naturels.
PCT/CA2000/001413 1999-11-29 2000-11-29 Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides WO2001039796A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020027006845A KR20020073341A (ko) 1999-11-29 2000-11-29 알츠하이머 및 아밀로이드 관련 질병의 예방 및 치료용 백신
IL14992400A IL149924A0 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP00981111A EP1235587A2 (fr) 1999-11-29 2000-11-29 Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides
MXPA02005576A MXPA02005576A (es) 1999-11-29 2000-11-29 Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
CA002388559A CA2388559A1 (fr) 1999-11-29 2000-11-29 Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides
BR0016022-9A BR0016022A (pt) 1999-11-29 2000-11-29 Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
AU18473/01A AU784312B2 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
JP2001541528A JP2004500354A (ja) 1999-11-29 2000-11-29 全ｄ体ペプチドを含む、アルツハイマー病およびアミロイド関連疾患の予防および処置のためのワクチン
NO20022531A NO20022531L (no) 1999-11-29 2002-05-28 Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
HK03100407.4A HK1049279A1 (zh) 1999-11-29 2003-01-16 預防及治療阿爾茨海默病(早老性痴呆)及澱粉樣蛋白有關的病之疫苗

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16859499P 1999-11-29 1999-11-29
US60/168,594 1999-11-29
US72484200A 2000-11-28 2000-11-28
US09/724,842 2000-11-28

Publications (2)

Publication Number Publication Date
WO2001039796A2 WO2001039796A2 (fr) 2001-06-07
WO2001039796A3 true WO2001039796A3 (fr) 2001-12-06

Family

ID=26864284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001413 WO2001039796A2 (fr) 1999-11-29 2000-11-29 Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides

Country Status (13)

Country Link
EP (1) EP1235587A2 (fr)
JP (1) JP2004500354A (fr)
KR (2) KR20080059676A (fr)
CN (1) CN1433321A (fr)
AU (1) AU784312B2 (fr)
BR (1) BR0016022A (fr)
CA (1) CA2388559A1 (fr)
HK (1) HK1049279A1 (fr)
IL (1) IL149924A0 (fr)
MX (1) MXPA02005576A (fr)
NO (1) NO20022531L (fr)
NZ (1) NZ540564A (fr)
WO (1) WO2001039796A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8835654B2 (en) 2004-12-22 2014-09-16 Bhi Limited Partnership Method and compositions for treating amyloid-related diseases
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0866805A1 (fr) 1995-12-12 1998-09-30 Karolinska Innovations AB PEPTIDE FIXANT LA SEQUENCE KLVFF DE L'AMYLOIDE $g(b)
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
KR20080017471A (ko) * 2000-02-21 2008-02-26 파멕사 에이/에스 아밀로이드의 하향-조절을 위한 신규한 방법
AU2007200047B2 (en) * 2000-07-07 2009-11-26 Bioarctic Neuroscience Ab Prevention and treatment of Alzheimer's disease
EP1309341A2 (fr) 2000-07-07 2003-05-14 Lars Lannfelt Prevention et traitement de la maladie d'alzheimer
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004005318A2 (fr) * 2002-07-03 2004-01-15 Bio Science International, Inc. Peptides comprenant des aminoacides d aromatiques et leurs methodes d'utilisation
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EP1658264A2 (fr) * 2003-06-23 2006-05-24 Neurochem (International) Limited Procedes et compositions de traitement de maladies associees aux amyloides
MY144231A (en) * 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
KR100851035B1 (ko) 2005-08-23 2008-08-11 대한민국 ＧＣＰ-Ⅱ를 유효성분으로 함유하는 β-아밀로이드의 뇌내축적 예방 및 치료용 약학적 조성물과 치료제 스크리닝용조성물 및 이를 이용한 스크리닝 방법
WO2007059000A2 (fr) 2005-11-10 2007-05-24 Roskamp Research, Llc Modulation de l'angiogenese au moyen de fragments de peptide a-beta
CA2631195C (fr) 2005-11-30 2016-04-05 Abbott Laboratories Anticorps monoclonaux et utilisation de ceux-ci
DK1959991T3 (da) * 2005-12-12 2013-06-17 Ac Immune Sa Terapeutisk vaccine
PT1960428E (pt) 2005-12-12 2011-10-07 Hoffmann La Roche Anticorpos glicosilados na região variável contra beta-amilóide 4
EP2325209A3 (fr) 2006-03-23 2011-08-03 BioArtic Neuroscience AB Anticorps améliorés sélectifs de protofibrilles et leur utilisation
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW201815827A (zh) * 2006-07-14 2018-05-01 瑞士商Ａｃ免疫公司 抗β-類澱粉抗體或其抗原結合片段、其用途及使用方法
EP2046833B9 (fr) 2006-07-14 2014-02-19 AC Immune S.A. Anticorps humanisé contre l'amyloid beta
BRPI0719763A2 (pt) * 2006-10-02 2014-01-28 Ac Immune Sa Anticorpo, molécula de ácido nucleico, vetor de expressão, célula, composição, mistura, uso de um anticorpo quimérico ou um fragmento do mesmo ou um anticorpo humanizado ou um fragmento do mesmo e/ou uma parte funcional e/ou uma composição farmacêutica ou uma mistura, métodos para a preparação de uma composição farmacêutica ou de uma mistura, para prevenir, tratar ou aliviar os efeitos de uma doença, de diagnóstico de uma doença ou condição associada com amilóide em um paciente e de determinação do grau da carga de placa amiloidogênica em um tecido e/ou fluidos corporais, kits de teste para a detecção e diagnóstico de doenças e condições associadas com amilóide, região variável de cadeia leve, região variável de cadeia pesada, linhagem de célula, gene de anticorpo, e, métodos para desagregar fibras de beta-amilóide pré formadas, para prevenir a degradação de neurônio induzida por abeta, para diagnosticar uma predisposição a uma doença ou condição associada com amilóide em um paciente, para monitorar doença residual mínima em um paciente, para prognosticar a responsividade de um paciente que é tratado com um anticorpo ou uma composição de vacina, para reduzir a carga de placa no cérebro de um animal, para reduzir a quantidade de placas no cérebro de um animal, para diminuir a quantidade total de abeta solúvel no cérebro de um animal e para reter ou aumentar a capacidade de memória cognitiva em um mamífero.
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
TR201802286T4 (tr) 2007-04-20 2018-03-21 The Chemo Sero Therapeutic Res Institute Peptidle bağışıklık yanıtının arttırılması için yöntem.
JP2010528583A (ja) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2182983B1 (fr) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Traitement de maladies amyloïdogéniques avec anti-abeta anticorps humanise
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009143489A2 (fr) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation d’angiogenèse par des fragments de peptide a-bêta
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2273273A1 (fr) 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibiteurs de la nitration de peptides ß amyloïdes et leurs utilisations pour le diagnostic et le traitement de la maladie d'Alzheimer
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
CA2985718A1 (fr) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anticorps anti-recepteur de la transferrine avec une affinite adaptee
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
JP7448174B2 (ja) * 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
KR20180094876A (ko) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
WO2018014126A1 (fr) 2016-07-18 2018-01-25 The University Of British Columbia Anticorps anti-bêta-amyloïde
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (fr) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de peptides beta-amyloides, comprenant des d-aminoacides
WO1999058564A1 (fr) * 1998-05-08 1999-11-18 Norsk Hydro Asa Mutants de dephasage de proteine de precurseur de beta-amyloide et d'ubiquitine-b et leur utilisation
WO2000068263A2 (fr) * 1999-05-05 2000-11-16 Neurochem, Inc. Peptides stereoselectifs antifibrillogenese et peptidomimetiques correspondants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (fr) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de peptides beta-amyloides, comprenant des d-aminoacides
WO1999058564A1 (fr) * 1998-05-08 1999-11-18 Norsk Hydro Asa Mutants de dephasage de proteine de precurseur de beta-amyloide et d'ubiquitine-b et leur utilisation
WO2000068263A2 (fr) * 1999-05-05 2000-11-16 Neurochem, Inc. Peptides stereoselectifs antifibrillogenese et peptidomimetiques correspondants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENKIRANE NADIA ET AL: "Antigenicity and immunogenicity of modified synthetic peptides containing D-amino acid residues: Antibodies to a D-enantiomer do recognize the parent L-hexapeptide and reciprocally.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 35, 1993, pages 26279 - 26285, XP002164690, ISSN: 0021-9258 *
VAN REGENMORTEL M H ET AL: "D - peptides as immunogens and diagnostic reagents.", CURRENT OPINION IN BIOTECHNOLOGY, (1998 AUG) 9 (4) 377-82. REF: 37, XP000990989 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8835654B2 (en) 2004-12-22 2014-09-16 Bhi Limited Partnership Method and compositions for treating amyloid-related diseases
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies

Also Published As

Publication number Publication date
IL149924A0 (en) 2002-11-10
KR20080059676A (ko) 2008-06-30
JP2004500354A (ja) 2004-01-08
CA2388559A1 (fr) 2001-06-07
BR0016022A (pt) 2002-08-06
HK1049279A1 (zh) 2003-05-09
NO20022531D0 (no) 2002-05-28
CN1433321A (zh) 2003-07-30
AU784312B2 (en) 2006-03-09
AU1847301A (en) 2001-06-12
EP1235587A2 (fr) 2002-09-04
MXPA02005576A (es) 2002-12-13
KR20020073341A (ko) 2002-09-23
NO20022531L (no) 2002-07-12
NZ540564A (en) 2007-04-27
WO2001039796A2 (fr) 2001-06-07

Similar Documents

Publication Publication Date Title
WO2001039796A3 (fr) Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides
WO2002096937A3 (fr) Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees au substances amyloides
WO2000072876A3 (fr) Prevention et traitement de maladies amyloidogenes
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
EP2258383A3 (fr) Peptides antigènes dérivés de la télomérase
WO2005087261A3 (fr) Identification d'antigenes autologues ou non autologues impliques dans des maladies auto-immunes
AU2002223640A1 (en) Fusion proteins as immunization treatments of alzheimer's disease
WO2003020764A3 (fr) Facteur ix modifie
BG66083B1 (bg) Фармацевтични състави, съдържащи антитела и антитела за профилактика и лечение на амилоидогенно заболяване
WO2000078344A8 (fr) Peptides proteiniques du prion et utilisations associees
WO2000076540A3 (fr) Proteines et vaccins de streptococcus pneumoniae
IL163812A (en) Immunizing composition, antigenic product and isolated antigenic peptide for inducing an immune response against beta-secretase cleavage site of amyloid the precursor protein
WO2001058485A3 (fr) Anticorps monoclonaux a vocation prophylactique et therapeutique
WO2000018351A3 (fr) Produits aglyco et utilisation de ceux-ci
WO2002059143A3 (fr) Peptides therapeutiques pour troubles de la demyelinisation
WO2001053457A3 (fr) Vaccins contre certains troubles neurodegeneratifs
PL371278A1 (en) Modified factor viii
WO2001014395A3 (fr) Nouveaux glycoconjuges et acides glycoamino leurs intermediaires et leurs utilisations
WO2002058725A3 (fr) Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2001058470A3 (fr) Procedes permettant d'ameliorer la biodisponibilite d'un medicament
WO2003055440A8 (fr) Compositions et methodes de traitement de maladies d'origine immune
WO2002070004A3 (fr) Immunogenes et vaccins ainsi que leur preparation et leur utilisation
MXPA04004970A (es) Epitopos de linfocitos t en carboxipeptidasa g2.
WO2001066740A3 (fr) Compositions et methodes de traitement de maladies d'origine immune
WO2002074332A3 (fr) Procede d'amelioration de l'immunogenicite d'un antigene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2002 200201317

Country of ref document: RO

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2388559

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 18473/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 519117

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2001 541528

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 149924

Country of ref document: IL

Ref document number: 1020027006845

Country of ref document: KR

Ref document number: 008164142

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005576

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000981111

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000981111

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027006845

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642